Daiichi-Sankyo begins Phase III for DU-176b for stroke prevention
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Daiichi-Sankyo is moving its Factor Xa inhibitor DU-176b into Phase III to prevent stroke and systemic embolic events in patients with atrial fibrillation. DU-176b will be the third oral, direct Factor Xa inhibitor to reach pivotal trials as companies race to market anticoagulants without warfarin's many complications (1Pharmaceutical Approvals Monthly October 2008, p. 3). Phase II studies showed two doses of DU-176b to be similar to warfarin in the incidence of major and clinically relevant non-major bleeding events, the firm said Dec. 8. The Phase III study will randomize approximately 16,500 patients to either 30 mg or 60 mg of DU-176b once daily or warfarin. The event-driven study has an expected median treatment duration of 24 months and is expected to conclude in 2012
You may also be interested in...
Last Of The Primary Care Blockbusters? New Antithrombotics Line Up To Unseat Warfarin, Heparins, Plavix
Although the mainstays of antithrombotic therapy have remained the same for decades, a lengthy R&D assault by pharma – including some of the largest clinical trials ever conducted – has produced potential game-changers that have made it to FDA review for both major blood clot approaches: anticoagulation and platelet inhibition.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.